Now Reading
Ubie, a Tokyo based HealthTech startup, announced today that it has raised JPY 2 B ($18.7M) in Series B financing

Ubie, a Tokyo based HealthTech startup, announced today that it has raised JPY 2 B ($18.7M) in Series B financing

  • Ubie has raised JPY2 billion ($18.7M) in Series B financing led by SUZUKEN CO.,LTD
  • Ubie is providing a AI-powered SaaS system to hospitals
Ubie Co-Founders Kota Kubo and Yoshinori Abe
Find Ubie on HealthTech Alpha

Ubie, which has thus far developed a number of AI-based healthcare products, has raised JPY2 billion ($18.7M) in Series B financing from SUZUKEN CO.,LTD, a Japanese pharmaceutical distributor that also entered into a strategic business partnership with Ubie.

With this new round of funding, Ubie seeks to realize rapid growth of its health-tech platforms, expand research and development capabilities, and staff its various sales and engineering teams. These funds will enable the company to quickly scale its Hospital SaaS (Software as a Service) product “Ubie for Hospital”, and its consumer application, AI symptom checker “Ubie”, to reach new partners and customers nationwide. In addition, Ubie also aims to expand its presence abroad in the near future as well.

“Against the backdrop of the COVID-19 pandemic, anxiety is increasing as the healthcare system is on the verge of collapse,” says Yoshinori Abe, Ubie co-founder and MD. “I strongly believe that our company is going to play a crucial role in combating the current crisis. During these uncertain times, our mission; “to develop a healthcare guide for everyone” has never been more important. With our AI-based symptom checker and clinical decision support technology, which we have been developing since 2013, we will make healthcare accessible to everyone by creating a “search engine” for healthcare. We are going to go full throttle to realize our company mission as soon as possible, with help from this fresh round of funding, and with the full support of all our stakeholders.”

“Today, technology supports every aspect of life” says Kota Kubo, AI engineer and co-founder of Ubie. “In the current coronavirus pandemic, new technologies are being utilized to stop the infection. However, many of the technologies and products that we use daily in Japan are developed by foreign tech companies. As a Japanese tech entrepreneur, this fact makes me disappointed and impatient. The COVID-19 situation is still very unpredictable, but progress to this point continues to prove to the world that Japan’s healthcare system is effective and resilient. I believe it is our turn to support our healthcare workers. I am confident that “made-in-Japan” tech companies such as ourselves are capable of leading dramatic change in this space. In order to further prepare our world-class healthcare system for the current pandemic, and for the future, we will continue to deliver products that combine medical expertise with the best technologies in the world.” 

See Also

About Ubie

Ubie is provider of two applications, AI monshin Ubie and Dr Ubie. AI Monshin Ubie is the AI-driven medical inquiry SaaS targeting users at medical institutions, to support document creation of clinical records under supervision of specialists. Using NLP and question-setting algorithm, it automatically creates clinical document templates using AI-driven inquiry according to each patient’s answer type. Dr. Ubie is a disease prediction app for general users. This app was developed based on AI technology to detect future risk for diseases. It also adopted the disease name prediction algorithm based on probability / statistical model and ML technology.

© 2020 Galen Growth Asia Pte Ltd. All Rights Reserved.

Scroll To Top

Overview

Category

Stage

Total Funding

Alpha Score

powered by